Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Ziresovir (AK0529) in Healthy Chinese Adults
NCT03322800Phase 1Completed
- Sponsor
- Ark Biosciences
- Start
- Oct 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ziresovir in respiratory syncytial virus infection (RSV) (6 arms), sponsored by Ark Biosciences. Primary endpoints: Maximum Observed Plasma Concentration at Day 10, Time to Maximum Plasma Concentration at Day 10 and 5 more. Started Oct 2017; status: completed.
02
Drugs
ziresovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03322800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03322800.